Clinical and laboratory features of patients with MDS at diagnosis
| . | All patients, N = 52 . |
|---|---|
| Age, median (IQR), y | 67 (57-76) |
| Female-to-male ratio | 1.6:1 |
| MDS according to the WHO 2016 classification, n (%) | |
| MDS-SLD | 4 (7.7) |
| MDS-MLD | 21 (40.4) |
| MDS with isolated 5q | 4 (7.7) |
| MDS-RS-SLD | 1 (1.9) |
| MDS-RS-MLD | 3 (5.8) |
| MDS EB-1 | 2 (3.8) |
| MDS EB-2 | 11 (21.2) |
| MDS/MPN-RS-T | 1 (1.9) |
| CMML | 5 (9.6) |
| Hb, median (IQR), g/dL | 8.6 (6.9-10.5) |
| ANC, median (IQR), ×109/L | 3.1 (1.2-5.4) |
| PLT, median (IQR), ×109/L | 81 (38-187) |
| LDH, median (IQR), U/L | 236 (158-335) |
| Hypocellular bone marrow, n (%) | 8 (15.4) |
| Bone marrow fibrosis, n (%) | 2 (3.8%) |
| Secondary MDS, n (%) | 10 (19.2%) |
| Ferritin, median (IQR), mg/dL | 541 (148-896) |
| Transfusion dependence, n (%) | 27 (51.9) |
| Bone marrow blast %, median (IQR) | 1.0 (0.0-9.0) |
| Cytogenetic, n (%) | |
| Without metaphase | 3 (5.8) |
| Normal | 36 (69.2) |
| 20q− | 2 (3.8) |
| 5q− | 4 (7.6) |
| 7−/7q− | 3 (5.7) |
| Y− | 1 (1.9) |
| Complex karyotype | 1 (1.9) |
| Other abnormalities | 2 (3.8) |
| IPSS-R, n (%) | 49 |
| Very low | 4 (8.2) |
| Low | 22 (44.9) |
| Intermediate | 9 (18.4) |
| High | 10 (20.4) |
| Very high | 4 (8.1) |
| Survival, median (95% CI), mo | 94 (75.8-112.2) |
| . | All patients, N = 52 . |
|---|---|
| Age, median (IQR), y | 67 (57-76) |
| Female-to-male ratio | 1.6:1 |
| MDS according to the WHO 2016 classification, n (%) | |
| MDS-SLD | 4 (7.7) |
| MDS-MLD | 21 (40.4) |
| MDS with isolated 5q | 4 (7.7) |
| MDS-RS-SLD | 1 (1.9) |
| MDS-RS-MLD | 3 (5.8) |
| MDS EB-1 | 2 (3.8) |
| MDS EB-2 | 11 (21.2) |
| MDS/MPN-RS-T | 1 (1.9) |
| CMML | 5 (9.6) |
| Hb, median (IQR), g/dL | 8.6 (6.9-10.5) |
| ANC, median (IQR), ×109/L | 3.1 (1.2-5.4) |
| PLT, median (IQR), ×109/L | 81 (38-187) |
| LDH, median (IQR), U/L | 236 (158-335) |
| Hypocellular bone marrow, n (%) | 8 (15.4) |
| Bone marrow fibrosis, n (%) | 2 (3.8%) |
| Secondary MDS, n (%) | 10 (19.2%) |
| Ferritin, median (IQR), mg/dL | 541 (148-896) |
| Transfusion dependence, n (%) | 27 (51.9) |
| Bone marrow blast %, median (IQR) | 1.0 (0.0-9.0) |
| Cytogenetic, n (%) | |
| Without metaphase | 3 (5.8) |
| Normal | 36 (69.2) |
| 20q− | 2 (3.8) |
| 5q− | 4 (7.6) |
| 7−/7q− | 3 (5.7) |
| Y− | 1 (1.9) |
| Complex karyotype | 1 (1.9) |
| Other abnormalities | 2 (3.8) |
| IPSS-R, n (%) | 49 |
| Very low | 4 (8.2) |
| Low | 22 (44.9) |
| Intermediate | 9 (18.4) |
| High | 10 (20.4) |
| Very high | 4 (8.1) |
| Survival, median (95% CI), mo | 94 (75.8-112.2) |
ANC, absolute neutrophil count; Hb, hemoglobin; MDS EB1, MDS excess blasts type 1; MDS EB2, MDS excess blasts type 2; MDS-MLD, MDS with multilineage dysplasia; MDS/MPN-RS-T, MDS/MPN ring sideroblasts with thrombocytosis; MDS-RS-MLD, MDS ring sideroblasts and multilineage dysplasia; MDS-RS-SLD, MDS ring sideroblasts and with single lineage; MDS-SLD, MDS with single lineage dysplasia; PLT, platelet count; WHO, World Health Organization.